Gain Therapeutics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Gain Therapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-42.7%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-42.7%
Rendimento futuro dei dividendi	n/a
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

May 29

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Jan 12

Gain Therapeutics appoints CEO

Sep 20

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Oct 27

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Aug 19

Gain Therapeutics EPS misses by $0.29

May 10

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di GANX siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di GANX siano aumentati.

Rendimento dei dividendi rispetto al mercato

Gain Therapeutics Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di GANX rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (GANX)	n/a
Fondo del 25% del mercato (US)	1.3%
Top 25% del mercato (US)	4.2%
Media del settore (Biotechs)	2.3%
Analista previsionale (GANX) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di GANX rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di GANX rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di GANX per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché GANX non ha segnalato alcun pagamento.

Gain Therapeutics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Gain Therapeutics, Inc. Announces Presentation of Preclinical Data for the Product Candidate, GT-02287

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Gain Therapeutics, Inc. Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Gain Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding MVLS Deficiency

Gain Therapeutics, Inc. Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

Gain Therapeutics, Inc. Announces CEO Changes

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $10.999898 million.

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

Consensus EPS estimates upgraded to US$0.97 loss, revenue downgraded

Gain Therapeutics, Inc., Annual General Meeting, Jun 24, 2024

Consensus revenue estimates fall by 40%

Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287

Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer

Independent Director recently bought US$116k worth of stock

Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

New major risk - Financial position

Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Consensus revenue estimates decrease by 11%, EPS upgraded

Gain Therapeutics, Inc. Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6.65573 million.

Gain Therapeutics, Inc. has filed a Follow-on Equity Offering.

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

Gain Therapeutics Presents New Preclinical Data Demonstrating A Reduction of Plasma Neurodegeneration Biomarker NfL After Administration of Its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.62 loss per share (vs US$0.43 loss in 2Q 2022)

Consensus revenue estimates increase by 193%, EPS downgraded

Consensus revenue estimates increase by 17%

Gain Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 24%

High number of new and inexperienced directors

Gain Therapeutics, Inc. Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson's Disease Patient-Derived Dopaminergic Neurons

Gain Therapeutics Announces Chief Executive Officer Changes

Gain Therapeutics appoints CEO

Gain Therapeutics, Inc. Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson's Disease

Price target decreased to US$19.25

Consensus forecasts updated

Consensus forecasts updated

Gain Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$22.00

High number of new and inexperienced directors

Price target decreased to US$22.00

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid

Gain Therapeutics Presents Preclinical Data on Its Structurally Targeted Allosteric Regulators in Gba1 Gaucher Disease At the Worldsymposium 2022

Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-Derived Ipsc Study Evaluating Star Compounds as A Treatment for Gaucher and Parkinson’S Disease

Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing

Gain Therapeutics EPS misses by $0.29

Gain Therapeutics, Inc. Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related a-synucleopathies at the XXVI IAPRD World Congress

Gain Therapeutics, Inc. has completed an IPO in the amount of $40.000004 million.

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti